{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T15:19:44Z","timestamp":1781104784880,"version":"3.54.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.vaccine.2026.128772","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T12:08:07Z","timestamp":1780315687000},"page":"128772","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Safety, immunogenicity, and dose ranging of a bivalent respiratory syncytial virus and human metapneumovirus glycoprotein F-molecular clamp vaccine candidate in older adults: 1-month interim analysis of an ongoing randomised, observer-blind, placebo- and active-controlled, phase 1 trial"],"prefix":"10.1016","volume":"87","author":[{"given":"Giovanni","family":"Della Cioppa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nischal","family":"Sahai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Dodeur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie L.","family":"Dutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Moller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jake S.","family":"O'Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Gillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smail","family":"Kulenovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith J.","family":"Chappell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juana","family":"Magdalena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Hanon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vaccine.2026.128772_bb0005","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ccm.2016.11.010","article-title":"Respiratory Syncytial Virus Infection: An Illness for All Ages","volume":"38","author":"Walsh","year":"2017","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.vaccine.2026.128772_bb0010","doi-asserted-by":"crossref","first-page":"135","DOI":"10.12688\/f1000research.12625.1","article-title":"Human metapneumovirus - what we know now","volume":"7","author":"Shafagati","year":"2018","journal-title":"F1000Res"},{"key":"10.1016\/j.vaccine.2026.128772_bb0015","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ijid.2014.03.1394","article-title":"Human metapneumovirus: review of an important respiratory pathogen","volume":"25","author":"Panda","year":"2014","journal-title":"Int J Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128772_bb0020","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/QCO.0000000000001124","article-title":"Respiratory syncytial virus prevention in immunocompromised hosts: gaps and opportunities","volume":"38","author":"Murray","year":"2025","journal-title":"Curr Opin Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128772_bb0025","doi-asserted-by":"crossref","DOI":"10.1111\/irv.13031","article-title":"Respiratory syncytial virus disease burden in adults aged 60 years and older in high-income countries: A systematic literature review and meta-analysis","volume":"17","author":"Savic","year":"2023","journal-title":"Influenza Other Respir Viruses"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128772_bb0030","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1007\/s40121-025-01187-2","article-title":"The Burden of Human Metapneumovirus (hMPV) Disease in Older and High-Risk Adults in Developed Countries: A Systematic Literature Review","volume":"14","author":"Sobanjo-Ter Meulen","year":"2025","journal-title":"Infect Dis Ther"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128772_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanhl.2024.100679","article-title":"The global burden of human metapneumovirus-associated acute respiratory infections in older adults: a systematic review and meta-analysis","volume":"6","author":"Kulkarni","year":"2025","journal-title":"Lancet Healthy Longev"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128772_bb0040","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa2209604","article-title":"Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults","volume":"388","author":"Papi","year":"2023","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.vaccine.2026.128772_bb0045","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1056\/NEJMoa2213836","article-title":"Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults","volume":"388","author":"Walsh","year":"2023","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.vaccine.2026.128772_bb0050","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1056\/NEJMoa2307079","article-title":"Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults","volume":"389","author":"Wilson","year":"2023","journal-title":"N Engl J Med"},{"issue":"309","key":"10.1016\/j.vaccine.2026.128772_bb0055","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac4241","article-title":"Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera","volume":"7","author":"Ngwuta","year":"2015","journal-title":"Sci Transl Med"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128772_bb0060","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1073\/pnas.1115941109","article-title":"Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention","volume":"109","author":"Magro","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128772_bb0065","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/s41467-022-28931-3","article-title":"Structure-based design of prefusion-stabilized human metapneumovirus fusion proteins","volume":"13","author":"Hsieh","year":"2022","journal-title":"Nat Commun"},{"issue":"48","key":"10.1016\/j.vaccine.2026.128772_bb0070","doi-asserted-by":"crossref","first-page":"12265","DOI":"10.1073\/pnas.1811980115","article-title":"Structure-based design of a quadrivalent fusion glycoprotein vaccine for human parainfluenza virus types 1-4","volume":"115","author":"Stewart-Jones","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128772_bb0075","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1038\/s41467-017-01708-9","article-title":"Structure and immunogenicity of pre-fusion-stabilized human metapneumovirus F glycoprotein","volume":"8","author":"Battles","year":"2017","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128772_bb0080","doi-asserted-by":"crossref","first-page":"e1059","DOI":"10.1016\/S2214-109X(24)00092-5","article-title":"Facilitating the development of urgently required combination vaccines","volume":"12","author":"Hausdorff","year":"2024","journal-title":"Lancet Glob Health"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128772_bb0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1013312","article-title":"A second-generation molecular clamp stabilised bivalent candidate vaccine for protection against diseases caused by respiratory syncytial virus and human metapneumovirus","volume":"21","author":"Young","year":"2025","journal-title":"PLoS Pathog"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128772_bb0090","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S1473-3099(21)00200-0","article-title":"Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial","volume":"21","author":"Chappell","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128772_bb0095","article-title":"Safety and immunogenicity of a SARS-CoV-2 spike, subunit vaccine stabilised in the prefusion conformation by second generation Molecular Clamp evaluated in adults aged 18\u201355 years: a randomised, double-blind, active comparator, Phase I trial","author":"Chappell","year":"2025","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128772_bb0100","series-title":"Handbook of methods for designing, monitoring, and analyzing dose-finding trials","first-page":"205","article-title":"The MCP-Mod methodology: practical considerations and the DoseFindingR package","author":"Xun","year":"2017"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128772_bb0105","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128772_bb0110","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaf160","article-title":"A randomized phase 1 clinical trial of a Respiratory Syncytial Virus and Human Metapneumovirus combination protein-based virus-like particle vaccine in adults 60-75 years of age","volume":"12","author":"Shapiro","year":"2025","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128772_bb0115","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1093\/infdis\/jiab611","article-title":"Phase 1\/2 Randomized Study of the Immunogenicity, Safety, and Tolerability of a Respiratory Syncytial Virus Prefusion F Vaccine in Adults With Concomitant Inactivated Influenza Vaccine","volume":"225","author":"Falsey","year":"2022","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128772_bb0120","doi-asserted-by":"crossref","first-page":"e996","DOI":"10.1093\/infdis\/jiae316","article-title":"Humoral Immunogenicity of mRNA-1345 RSV Vaccine in Older Adults","volume":"230","author":"Goswami","year":"2024","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128772_bb0125","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S2213-2600(25)00048-7","volume":"13","author":"Ison","year":"2025","journal-title":"Lancet Respir Med"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128772_bb0130","doi-asserted-by":"crossref","first-page":"e905","DOI":"10.1093\/infdis\/jiae185","article-title":"Respiratory syncytial virus prefusion F vaccination: antibody persistence and revaccination","volume":"230","author":"Walsh","year":"2024","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128772_bb0135","article-title":"Development, current status, and remaining challenges for Respiratory Syncytial Virus vaccines","volume":"13","author":"Anastassopoulou","year":"2025","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128772_bb0140","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac693","article-title":"Antibody correlates of protection from severe Respiratory Syncytial Virus disease in a vaccine efficacy trial","volume":"10","author":"Fong","year":"2023","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128772_bb0145","article-title":"Immune correlates analysis of mRNA-1345 RSV vaccine efficacy clinical trial","volume":"16","author":"Ma","year":"2025","journal-title":"Nat Commun"},{"issue":"24","key":"10.1016\/j.vaccine.2026.128772_bb0150","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1016\/S0264-410X(03)00355-4","article-title":"Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies","volume":"21","author":"Piedra","year":"2003","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26005815?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26005815?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T14:52:34Z","timestamp":1781103154000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26005815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":30,"alternative-id":["S0264410X26005815"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128772","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety, immunogenicity, and dose ranging of a bivalent respiratory syncytial virus and human metapneumovirus glycoprotein F-molecular clamp vaccine candidate in older adults: 1-month interim analysis of an ongoing randomised, observer-blind, placebo- and active-controlled, phase 1 trial","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128772","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128772"}}